



ASX / MEDIA RELEASE

Investor Conference Call

Brisbane, Australia, 9 August 2017 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, will host a conference call on **Thursday 10 August at 10:30am AEST** to discuss the preliminary top-line results from its SMARTCOUGH-C study. Tony Keating, Managing Director and CEO, will host the call.

Conference Call Details:

Date: Thursday 10 August, 10:30am AEST

Conference ID: 6884 2208

Access:

- Australia: +61 2 8038 5221
- New Zealand: 0800 452 782
- China: 4001 203 085
- Hong Kong: 800 908 865
- Singapore: 800 616 2288
- United Kingdom: 0808 234 0757
- United States: 1855 293 1544

Participants will need to provide their name and to ask a question, they will need to dial “*1” (star, 1) on their telephone keypad.

A recording will be available four hours after the end of the call on openbriefing.com.

About the SMARTCOUGH-C Study

SMARTCOUGH-C is a multi-site, double blind, prospective clinical study to investigate ResAppDx for the diagnosis of respiratory disease in infants and children using cough sounds. The study has enrolled 1,245 patients aged 29 days to 12 years. The co-primary endpoints of the study are the diagnosis of pneumonia compared to clinical and radiologic diagnosis. Secondary endpoints are diagnosis of upper respiratory tract infection, lower respiratory involvement, croup, asthma/reactive airways disease and bronchiolitis compared with a clinical diagnosis. A range of smartphone models are used. Details of the study can be found at www.clinicaltrials.gov (NCT02973282).

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 22, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 **E** info@resapphealth.com.au **W** www.resapphealth.com.au



About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma, pneumonia and upper respiratory tract infections in adults. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as global aid and humanitarian organisations in the developing world.

For more information on ResApp, visit www.resapphealth.com.au

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director and
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 22, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 **E** info@resapphealth.com.au **W** www.resapphealth.com.au